research Treatment of Pediatric Alopecia Areata: A Systematic Review
Topical corticosteroids are the best initial treatment for children's alopecia areata.
Search
for
Sort by
Research
150-180 / 521 results
research Tofacitinib: A Promising Treatment for Adolescent Alopecia Areata
Tofacitinib may be an effective and safe treatment for hair loss in teenagers with alopecia areata.
research Excellent Response to Tofacitinib Treatment in a Patient with Alopecia Universalis
A patient with complete hair loss regrew all her hair using tofacitinib.
research Folliculitis Decalvans Responsive to Tofacitinib: A Case Series
Tofacitinib may effectively treat folliculitis decalvans.
research Recalcitrant Lichen Planopilaris Treated with Upadacitinib: A Case Series
Upadacitinib may effectively treat resistant lichen planopilaris.
research Systematic Review of Newer Agents for the Management of Alopecia Areata in Adults: Janus Kinase Inhibitors, Biologics and Phosphodiesterase-4 Inhibitors
New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.
research Comparison of Ruxolitinib and a Collagen-Targeted PTH-Based Hair Cycle Stimulant on Hair Follicle Counts and Hair Growth in the C3H/HeJ Engrafted Mouse Model of Alopecia Areata
The PTH-CBD injection improved hair regrowth better than the daily ruxolitinib pill in mice.
research The Efficacy of Baricitinib as a Treatment Option for Alopecia in Terms of Promoting Hair Regrowth and Improving Patient Reported Outcomes
Baricitinib effectively promotes hair regrowth in severe alopecia with minimal side effects.
research Treatment of Lichen Planopilaris With Janus Kinase Inhibitors
Janus kinase inhibitors may help treat lichen planopilaris.
research Patient Experience of Off-Label Janus Kinase Inhibitor Use for Alopecia Areata in a Cohort of 34 Patients From a Single UK Practitioner: Exploring Changing Trends in Healthcare Provision and Access to Drug Treatments
Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.
research Alopecias in Humans: Biology, Pathomechanisms, and Emerging Therapies
New treatments for hair loss are emerging as we better understand hair growth and its genetic causes.
research Hair Today, Gone Tomorrow: Potential of Tofacitinib and Ruxolitinib in Treating Hair Loss
Two drugs, tofacitinib and ruxolitinib, may help regrow hair by activating hair follicles.
research The Role of Oclacitinib in the Management of Ischemic Dermatopathy in Four Dogs
Oclacitinib effectively treated a skin condition in dogs that didn't respond to other immunosuppressants.
research Topical Ruxolitinib for the Treatment of Alopecia Universalis
Topical Ruxolitinib may safely treat severe hair loss.
research Novel Investigational Drugs for Alopecia Areata and Future Perspectives
JAK inhibitors are safe and effective for treating moderate-to-severe alopecia areata.
research EE325 Budget Impact of Baricitinib for Patients with Severe Alopecia Areata
Adding Baricitinib for severe alopecia areata will have a small impact on a health plan's budget.
research Acne Exacerbation After Tofacitinib Treatment for Alopecia Areata
Tofacitinib treatment for hair loss may worsen acne.
research Topical Janus Kinase Inhibitors for the Treatment of Pediatric Alopecia Areata
Topical JAK inhibitors may help children with alopecia areata regrow hair.
research A Description of Alopecia Areata in European Patients Based on Real-World Survey Data: Physician-Reported Characterization of Severity and Associated Treatment Utilization
More effective treatments are needed for severe alopecia areata.
research Selectively Targeting JAK1 or JAK3 Pathway Is Sufficient to Reverse Alopecia Areata
Blocking JAK1 or JAK3 helps reverse hair loss in a mouse model of alopecia areata.
research Treatment of Alopecia Universalis with Topical Janus Kinase Inhibitors – A Double Blind, Placebo, and Active Controlled Pilot Study
Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.
research Review of Baricitinib in the Treatment of Alopecia Areata
Baricitinib is a relatively safe and effective treatment for severe alopecia areata.
research Efficacy and Safety of Baricitinib in Managing Severe Alopecia Areata: A 6-Month Real-World Experience
Baricitinib was effective and safe for severe hair loss treatment over 6 months.
research Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition
Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.
research Tofacitinib in the Management of Alopecia Universalis
Tofacitinib helped a woman regrow hair with no major side effects.
research Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database
People with Alopecia Areata have more herpes simplex infections but similar rates of cancer, blood clots, and heart disease compared to those without it.
research Comparison of Ruxolitinib and a Collagen-Targeted PTH-Based Hair Cycle Stimulant on Hair Follicle Counts and Hair Growth in the C3H/HeJ Engrafted Mouse Model of Alopecia Areata
A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.
research JAK Inhibition in the Treatment of Alopecia Areata: A Promising New Dawn?
JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.
research Effectiveness of OR-101, a Next Generation Highly Selective JAK3 Inhibitor, in a Humanized Murine Model of Alopecia Areata
OR-101 shows promise for treating alopecia areata by improving hair growth.
research Expression of Programmed Cell Death 1 Inversely Correlated With the Density of CD8+ T Cells Infiltrating Hair Follicles in Alopecia Areata
Higher PD-1 levels are linked to fewer immune cells in hair follicles in alopecia areata.